Introduction
In vitro diagnostics, the tests that analyze blood, tissue, or other biological samples outside the body, have historically sat somewhat in the shadow of therapeutics and implantable devices in regulatory affairs hiring conversations. That is shifting. Molecular diagnostics, companion diagnostics tied to targeted therapies, point-of-care testing, and laboratory-developed tests have all expanded meaningfully in recent years, and the regulatory frameworks governing them have grown more demanding at the same time. Together these trends are creating a distinct, and increasingly sought-after, regulatory affairs specialization. Understanding why this niche is growing, and what makes IVD regulatory work different from device or drug regulatory work more broadly, is useful both for professionals considering a move into it and for anyone trying to read where hiring demand in the broader field is heading.
Why IVD Regulatory Work Is Expanding
Several forces are converging to expand the IVD regulatory function specifically. Precision medicine has made companion diagnostics, tests that determine whether a specific patient is likely to respond to a specific therapy, a standard part of drug development for many targeted treatments, which means every company developing that kind of therapy now needs regulatory expertise spanning both the drug and its paired diagnostic. Molecular and genomic testing has expanded rapidly as sequencing costs have fallen, creating a larger population of test developers who need regulatory support for products that did not meaningfully exist a decade or two ago in the same commercial volume. Point-of-care and at-home testing has also grown, driven partly by consumer demand for faster results and partly by health systems looking to decentralize testing away from central laboratories.
At the same time, the regulatory bar for many of these products has risen. In the European Union, the In Vitro Diagnostic Regulation reclassified a large share of tests into higher-risk categories that now require notified body involvement, a significant change from the prior directive under which most IVDs were self-certified by the manufacturer. That single shift alone increased the volume of regulatory work required per product meaningfully, and it increased demand for people who understand IVD-specific technical documentation, performance evaluation, and notified body engagement. In the United States, oversight of laboratory-developed tests has also been an active and evolving area, adding another layer of complexity that regulatory professionals in this space need to track closely.
What Makes IVD Regulatory Work Distinct
IVD regulatory affairs draws on the same core regulatory skill set as device or drug regulatory work, understanding submission requirements, structuring evidence, engaging with health authorities, but it requires its own specific technical fluency. A central concept in IVD regulatory work is the distinction between analytical validity, whether a test accurately and reliably measures what it claims to measure, and clinical validity, whether that measurement is meaningfully associated with the clinical condition or outcome the test is meant to inform. Building and presenting evidence for both is a core part of the job, and it requires regulatory professionals to work closely with assay development scientists and biostatisticians in a way that is somewhat unique to this product category.
IVD regulatory professionals also need familiarity with the specific classification logic that governs these products, which in most major markets is risk-based and depends heavily on factors like whether a wrong result could lead to a seriously harmful clinical decision, whether the test is used for screening a broad population or diagnosing an already-suspected condition, and whether the test informs a treatment decision directly, as with a companion diagnostic. Getting classification right early has an outsized effect on the rest of the regulatory pathway, which makes sound judgment on this point one of the most valuable skills an IVD regulatory professional can bring.
Companion Diagnostics as Their Own Specialty
Within IVD regulatory work, companion diagnostics have emerged as a specialty within the specialty. Because a companion diagnostic is developed and reviewed alongside the therapy it pairs with, regulatory professionals working in this space need to coordinate closely with the therapeutic product's regulatory team, often across two different submission types and sometimes two different review divisions within the same health authority. Timelines for the diagnostic and the drug typically need to stay tightly aligned, since regulatory approval of the therapy in many cases depends on the diagnostic being approved or at least sufficiently advanced in its own review. Professionals who can operate comfortably at that intersection, understanding both the diagnostic-specific requirements and how they interact with a therapeutic development timeline, are in a genuinely distinct and narrower talent pool than general IVD regulatory expertise alone.
Where the Hiring Demand Is Concentrated
Demand for IVD regulatory expertise shows up across several types of employers. Established diagnostics manufacturers need it for their core product lines, and as their portfolios shift toward more molecular and companion diagnostic products, they need regulatory staff who can handle the added complexity those categories bring. Pharmaceutical and biotech companies developing targeted therapies increasingly need in-house or consultant support for the companion diagnostic component of their programs, even when the diagnostic itself may ultimately be manufactured by a diagnostics partner. Smaller diagnostics startups, particularly in molecular and genomic testing, often need regulatory expertise earlier in their life cycle than product volume alone would suggest, precisely because getting classification and evidence strategy right from the beginning avoids costly rework later. And consultancies serving all of the above have expanded their IVD-specific practices to meet client demand across each of these employer types.
Skills Worth Building for This Niche
For a regulatory professional considering a move toward IVD work, a few areas of skill-building pay off disproportionately. Direct familiarity with the IVDR's classification rules and technical documentation requirements is valuable given how significantly that framework changed the landscape. Comfort reading and engaging with clinical and analytical performance data, even without a background as a bench scientist, helps enormously, since so much of IVD regulatory strategy hinges on how that evidence is generated and presented. Exposure to companion diagnostic development, even at the periphery of a program rather than leading it, is a strong differentiator given how specialized that intersection is. And general familiarity with how molecular and genomic technologies work, without needing deep technical mastery, makes it much easier to have credible conversations with the scientists generating the underlying data. It is also worth building a working understanding of how reimbursement and clinical adoption interact with regulatory strategy for diagnostics specifically, since a diagnostic that clears regulatory approval but lacks a clear path to being ordered and paid for in routine practice often struggles commercially regardless of its technical merit, and regulatory professionals who can speak credibly to that broader picture are more valuable to the teams making launch decisions.
Point-of-Care and At-Home Testing as a Growing Sub-Niche
A related but distinct pocket of hiring demand sits in point-of-care and at-home testing, tests designed to be run outside a central laboratory, sometimes by a clinician at the bedside and sometimes by a consumer with no clinical training at all. Regulatory work in this space carries its own particular considerations layered on top of standard IVD requirements: usability and human factors evidence matters far more when the intended operator is a layperson rather than a trained technician, and the regulatory strategy has to account realistically for how the test will actually be used outside a controlled laboratory environment. Manufacturers expanding into this space, including some device and diagnostics companies that historically focused only on laboratory-based testing, increasingly need regulatory professionals who understand both the standard IVD framework and this human factors layer, which has made the combination a genuinely differentiated skill set rather than a simple extension of laboratory-based IVD experience.
A Note on Overlap With Broader Medical Device Regulatory Work
It is worth being clear that IVD regulatory work is not a fully separate profession from medical device regulatory affairs more broadly. Many organizations maintain a combined device and diagnostics regulatory function, and professionals frequently move between the two categories over a career. What is changing is not that IVD work is splitting off entirely, but that the volume and technical depth required in the IVD segment specifically has grown enough that employers increasingly value candidates who can point to direct experience with diagnostic-specific classification, evidence, and submission requirements, rather than assuming general device experience transfers completely. For professionals already working in general medical device or pharmaceutical regulatory roles who want to move toward this niche, the most credible path is usually to seek out a project or a rotation that touches a diagnostic component directly, a companion diagnostic workstream, an IVDR technical file, a point-of-care usability study, rather than waiting for a fully IVD-titled role to open, since firsthand exposure to the specific evidence and classification questions this category raises is what employers are actually screening for.
Conclusion
In vitro diagnostics has moved from a relatively quiet corner of regulatory affairs to one of the more actively growing niches in the field, driven by the expansion of precision medicine, molecular testing, and point-of-care diagnostics, alongside a meaningfully higher regulatory bar in major markets. For regulatory professionals, building specific fluency in analytical and clinical validity, IVD classification logic, and the particular demands of companion diagnostic development is a credible way to differentiate yourself in a segment of the job market that shows every sign of continuing to grow.